MétaCan
Menu
Back to cohort
Record W2604146377 · doi:10.1111/ejh.12891

Is allogeneic stem cell transplantation for myelofibrosis still indicated at the time of molecular markers and <scp>JAK</scp> inhibitors era?

2017· article· en· W2604146377 on OpenAlexaff
Elsa Lestang, Pierre Péterlin, Yannick Le Bris, Viviane Dubruille, Jacques Delaunay, Catherine Godon, Olivier Theisen, Nicolas Blin, Beatrice Mahé, Thomas Gastinne, Alice Garnier, Cyrille Touzeau, Maud Voldoire, Marie C. Béné, Steven Le Gouill, Nöel Milpied, Mohamad Mohty, Philippe Moreau, Thierry Guillaume, Patrice Chevallier

Bibliographic record

VenueEuropean Journal Of Haematology · 2017
Typearticle
Languageen
FieldMedicine
TopicMyeloproliferative Neoplasms: Diagnosis and Treatment
Canadian institutionsHotel Dieu Hospital
Fundersnot available
KeywordsMyelofibrosisMedicineInternational Prognostic Scoring SystemRuxolitinibInternal medicineUnivariate analysisTransplantationAutologous stem-cell transplantationOncologyStem cellOverall survivalGastroenterologyMyeloid leukemiaHematopoietic stem cell transplantationMyelodysplastic syndromesMultivariate analysisSurgeryBone marrow

Abstract

fetched live from OpenAlex

Abstract Objective The role of allogenic stem cell transplantation (ASCT) is still debated in myelofibrosis (MF). Methods A retrospective analyzed was performed to compare the outcome of 71 patients with intermediate‐2 or high‐risk Dynamic International Prognosis Scoring System+ (DIPSS+) primary (PMF) or secondary (SMF) myelofibrosis with an indication of ASCT as they ultimately underwent the procedure (n=34) or not (n=37). Results Five‐year overall survival (OS) was not statistically different between both groups (allograft: 52% vs no allograft: 34%, P=.12). However, progression to myelodysplastic syndrome or acute myeloid leukemia at 5 years was significantly lower in transplanted patients (14% vs 50%, P=.01). In univariate analysis, 5‐year OS was significantly higher for transplanted vs non‐transplanted patients with unfavorable karyotype (75% vs 0%, P=.001), SMF (71% vs 20%, P=.001) or high DIPSS+ score (46% vs 15%, P=.03). There was also a trend for better 5‐year OS in allografted patients with high JAK2V617F burden (>65%) (75% vs 8%, P=.07). Interestingly, the survival of patients who did not proceed to ASCT was dramatically increased by the use of ruxolitinib. Conclusions Not all intermediate‐2/high‐risk DIPSS+ MF patients benefit from ASCT, especially since the introduction of JAK2 inhibitors.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Theoretical or conceptual · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.001
Threshold uncertainty score0.004

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.014
GPT teacher head0.248
Teacher spread0.234 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designTheoretical or conceptual
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations5
Published2017
Admission routes1
Has abstractyes

Explore more

Same venueEuropean Journal Of HaematologySame topicMyeloproliferative Neoplasms: Diagnosis and TreatmentFrench-language works237,207